Patent expiry expected early 2026. Reserve your spot now, no payment required.
Limited time, early access

Major savings on Semaglutide are coming to Canada.

The active ingredient in Ozempic® and Wegovy® loses its Canadian patent in early 2026. Generic alternatives will follow, often at a fraction of the brand price. Reserve your spot for first access.

No payment required
Cancel anytime
Privacy protected

Join the waitlist

Be first in line the moment generics become available.

By joining the waitlist, you consent to Canshipmeds contacting you about generic semaglutide availability. We do not share your information. You can unsubscribe at any time.

Your information stays private and secure

You're on the list

We'll reach out the moment generic semaglutide options are available for dispensing. Keep an eye on your inbox.

Why join the waitlist

Three reasons to reserve your spot

Generic launches move fast, and supply often gets allocated before most patients hear about them. Our waitlist exists to make sure you're not the last to know.

N°01

Front of the line

Be the first to know the moment lower cost generic options become available for dispensing. Notifications go out to waitlist members before any public announcement.

N°02

Price drop alerts

Receive early notification of anticipated price drops as more generic competitors enter the market. We track manufacturer pricing so you don't have to.

N°03

Zero obligation

Joining is free. You're never charged for being on the list, and you can unsubscribe at any time. We only contact you with information relevant to your savings.

Illustrative example
Brand name
Monthly cost
$$$$
↓
Generic option
Expected pricing
$$
About Semaglutide

What's actually happening in 2026.

Semaglutide is the active ingredient in Ozempic® (for type 2 diabetes) and Wegovy® (for chronic weight management). Both are made by Novo Nordisk and are currently sold at premium prices because they're under patent protection in Canada.

That patent is approaching expiry in early 2026. Once it lapses, other licensed manufacturers can legally produce generic versions of the same molecule. Historically, generic competition can reduce drug prices significantly within the first year.

We're preparing now so our patients can move first when supply opens up.

2026
Expected year of Canadian patent expiry for semaglutide
$0
Cost to join the waitlist. No card, no commitment
Common questions

Things people ask before joining

Semaglutide is a GLP-1 receptor agonist, a class of medication that mimics a hormone your body produces to regulate blood sugar and appetite. It's the active molecule in Ozempic® (prescribed for type 2 diabetes) and Wegovy® (prescribed for chronic weight management). Both are currently brand name products. Once the patent expires, generic manufacturers can legally produce the same molecule under different names.
The Canadian patent for semaglutide is expected to expire in early 2026. The exact date can shift due to legal proceedings, regulatory review, and manufacturer readiness. We'll notify waitlist members the moment confirmed availability is announced.
No. Joining is completely free, and you're never charged for being on the list. There's no payment method required, no auto-renewal, nothing to cancel. You can leave the list at any time by replying to one of our emails.
Primarily by email. If you provide your phone number, we may send a text or call when generics are confirmed available, since timing can be tight. We only use your contact information for waitlist updates and nothing else.
Yes. Your information is stored securely and never sold or shared with third parties. We follow Canadian privacy law (PIPEDA) and provincial health information requirements. You can request deletion of your data at any time.
Yes. Semaglutide is a prescription medication in Canada, and that will remain true for generic versions. If you don't yet have a prescription, we can connect you with a licensed prescriber to discuss whether the medication is appropriate for you.
Don't miss the moment

Reserve your spot today.

Stock for this historic shift in GLP-1 pricing will be limited at launch. Join the waitlist now and we'll make sure you're first in line.

Join the waitlist